Skip to content

The Oncology Institute, Inc. TOI Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
0
GRAIL, Inc. logo
GRAIL, Inc.GRAL
0
McKesson logo
McKessonMCK
Summit Therapeutics logo
Summit TherapeuticsSMMT
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s convertible preferred stock issued shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s convertible preferred stock issued shares?
The Oncology Institute, Inc. (TOI) reported convertible preferred stock issued shares of 193.5K in Q1 2026.
How has The Oncology Institute, Inc.'s convertible preferred stock issued shares changed year-over-year?
The Oncology Institute, Inc.'s convertible preferred stock issued shares decreased by 4.3% year-over-year, from 202.3K to 193.5K.
What is the long-term trend for The Oncology Institute, Inc.'s convertible preferred stock issued shares?
Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s convertible preferred stock issued shares has grown at a 4.3% compound annual growth rate (CAGR), from 163.5K to 193.5K.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.